Citius Oncology, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-24.8M | $-21.1M | $2.4M | $380.8K |
| Depreciation & Amortization | — | — | — | — |
| Depreciation | — | — | — | — |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $8.3M | $7.5M | $2.0M | — |
| Net Cash from Operating Activities | $-5.5M | $126.4K | $-601.3K | $-48.0K |
| Investing Activities | ||||
| Capital Expenditures | — | — | — | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-5.8M | $-5.0M | $-1.3M | $-67.3M |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $15.2M | $4.9M | $1.7M | $67.7M |
| Net Change in Cash | — | — | $-256.4K | $289.2K |
| Free Cash Flow | — | — | — | — |